Objectives:Endothelial monocyte-activating polypeptide-2 (EMAP-2) is a novel protein that demonstrates potent proinflammatory activity in vivo and in vitro. The purpose of this study was to investigate the expression of EMAP-2 in normal pregnancy and in pregnancies complicated with preeclampsin and to test the hypothesis that EMAP-2 is a causative agent of the endothelial activation of preeclampsia.
Methods:Expression of EMAP-2 in the placenta was investigated using reverse transcriptase-polymerase chain reaction to detect mRNA, and immunohistochemistry with an EMAP-2-specific polyclonal antiserum was carried out to detect protein. Levels of circulating EMAP-2 protein were measured in the blood of nonpregnant, normal pregnant, and preeclamptic individuals using a specific enzyme-linked immunoabsorbent assay and the molecular forms present assessed by Western blotting.
Results:EMAP-2 is transcribed and translated by the placenta thoughout pregnancy and in preeclampsia and can be detected in the plasma of nonpregnant and pregnant individuals. Levels of circulating EMAP-2 antigen are raised in pregnancy compared with nonpregnant controls; however, levels in patients with preeclampsia are identical to those in normal pregnant individuals.
Conclusion:While circulating levels of EMAP-2 are increased in pregnancy, there is no evidence that EMAP-2 is involved directly in the pathogenesis of preeclampsia.
1. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Pre-eclampsia: an endothelial cell disorder. Am J Obstet Gynecol1989;161:1200-1204.
2.
2. Rodgers G. Hemostatic properties of normal and perturbed vascular cells. FASEB J1988;2:116-123.
3.
3. McCartney CP. The acute hypertensive disorders of pregnancy classified by renal histology. Gynaecologia1969;167:214-220.
4.
4. Brown MA, Zammit VC, Lowe SA. Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension. Clin Sci1989;77:599-604.
5.
5. Roberts JM, Edep ME, Goldfein A, Taylor RN. Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro. Am J Reprod Immunol1992;27:101-108.
6.
6. Taylor RN, Crombleholme WR, Friedman SA, Jones LA, Casal DC, Roberts JM. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol1991;165:895-901.
7.
7. Roberts JM, Redman C. Pre-eclampsia: More than pregnancy-induced hypertension. Lancet1993;341:1447-1451.
8.
8. Baker PN, Davidge ST, Roberts JM. Plasma from preeclamptic women increases endothelial cell nitric oxide production. Hypertension1995;26:244-248.
9.
9. Ashworth JR, Baker PN, Warren AY, Johnson IR. Loss of endothelial dependent relaxation in myometrial resistance arteries in pre-eclampsia. Br J Obstet Gynaecol1997;104:1152-1158.
11. Kao J, Ryan J, Brett J, et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem1992;267:20239-20247.
12.
12. Tas MP, Houghton J, Jakobsen AM, Tolmachova T, Carmichael J, Murray JC. Cloning and expression of human endothelial-monocyte-activating polypeptide 2 (EMAP-2) and identification of its putative precursor. Cytokine1997;9:535-539.
13.
13. Tas MPR, Murray JC. Endothelial-monocyte-activating polypeptide II. Int J Bio Cell Biol1996;28:837-841.
14.
14. Kao J, Houck K, Fan Y, et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem1994;269:25106-25119.
15.
15. Kao J, Fan YG, Haehnel I, et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem1994;269:9774-9782.
16.
16. Schwarz M, Brett J, Li J, et al. Endothelial-monocyte activating polypeptide (EMAP) II, a novel antiangiogenic protein, suppresses tumor growth and induces apoptosis in endothelial cells. Circulation1995;92:1-7.
17.
17. Smith SC, Baker PN, Symonds EM. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol1997;177:1395-1401.
18.
18. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. In: Sharp F, Symonds EM, eds. Hypertension in pregnancy. Proceedings of the 16th study group of the RCOG. Ithaca, New York: Perinatology Press, 1986:401-407.
19.
19. Wilcox MA, Johnson IR, Maynard PV, Smith SJ, Chilvers CED. The individualised birthweight ratio: A more logical outcome measure of pregnancy than birthweight alone. Br J Obstet Gynaecol1993;100:342-347.
20.
20. Chard T. Cytokines in implantation. Hum Reprod Update1995;1:385-396.
